FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
- What is Chronic immunotoxicity of immune checkpoint inhibitors?
- This anti-aging medicine has gone astray: Chronic inflammation leads to a decrease in NAD+
- FDA Approved Treatment Funded by Ice Bucket Challenge Donors
- Similar to HIV: Another deadly monkey virus may spread to humans
- 2022 Nobel Prize Winner Paper: The risk of severe COVID-19 is inherited from Neanderthals
- Breakthrough method ‘starves’ highly lethal cancer tumors and eradicates them
FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
On May 05, U.S. Food and Drug Administration (FDA) announced on the same day that they would limit the emergency use authorization of Johnson & Johnson’s COVID-19 vaccine because it May cause rare and dangerous thrombocytopenic blood clots in recipients.
With immediate effect, Johnson & Johnson’s COVID-19 vaccine in the United States will be limited to adults over the age of 18 who cannot receive other vaccines.
Screenshot from CNN website
Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said the center has been monitoring the incidence of thrombocytopenic blood clots following Johnson & Johnson’s COVID-19 vaccine and is updating the emergency use authorization through its “safety surveillance system.” .
Marks said that the FDA’s move this time reflects the power of the “safety surveillance system” and also shows that they are determined to use science and data to guide action.
CNN confirmed to the FDA that this restriction also applies to booster shots.
The FDA believes that for certain groups of people, the risks of J&J’s COVID-19 vaccine already outweigh the benefits, but they can still receive J&J’s COVID-19 vaccine for the following groups: Severe allergic reaction to Pfizer or Moderna’s mRNA COVID-19 vaccine Those who have personal doubts about the mRNA COVID-19 vaccine, if they do not receive the Johnson & Johnson COVID-19 vaccine, they will not be vaccinated; those who cannot receive the mRNA COVID-19 vaccine.
According to the U.S. Centers for Disease Control and Prevention (CDC), more than 18.7 million doses of Johnson & Johnson’s COVID-19 vaccine have been administered in the United States. Among those in the U.S. who have been fully vaccinated, 7.7% of the people who received the Johnson & Johnson vaccine were vaccinated.
According to the FDA’s statistics as of March 18, they have confirmed 60 cases of thrombocytopenic blood clots after vaccination with Johnson & Johnson’s COVID-19 vaccine, including 9 deaths.
Should Johnson & Johnson COVID-19 vaccine be used for booster?
FDA restricts Johnson & Johnson COVID-19 vaccine due to risks of blood clots
(source:internet, reference only)
Disclaimer of medicaltrend.org
